| 6.44 -0.37 (-5.43%) | 11-02 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 8.2 | 1-year : | 8.93 |
| Resists | First : | 7.02 | Second : | 7.65 |
| Pivot price | 6.61 |
|||
| Supports | First : | 6.01 | Second : | 5 |
| MAs | MA(5) : | 6.84  |
MA(20) : | 6.7 |
| MA(100) : | 6.8 |
MA(250) : | 8.7 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 61.1 |
D(3) : | 71 |
| RSI | RSI(14): 46.4 |
|||
| 52-week | High : | 14.06 | Low : | 4.36 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ EBS ] has closed above bottom band by 36.7%. Bollinger Bands are 17.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 7.31 - 7.35 | 7.35 - 7.37 |
| Low: | 6.68 - 6.72 | 6.72 - 6.75 |
| Close: | 6.74 - 6.81 | 6.81 - 6.86 |
Emergent BioSolutions Inc. is a life sciences company dedicated to providing vital preparedness and response solutions for a wide range of public health threats (PHTs) across the United States. These threats encompass accidental, deliberate, and naturally occurring events, including chemical, biological, radiological, nuclear, and explosives (CBRNE) incidents, emerging infectious diseases, travel-related health risks, and acute emergency care situations. The company's current product portfolio features essential vaccines and treatments such as BioThrax for anthrax and ACAM2000 for smallpox. It also offers Botulism Antitoxin Heptavalent, vaccinia immune globulin intravenous to manage smallpox vaccine complications, and inhalational anthrax therapies like raxibacumab and Anthrasil. Other key offerings include reactive skin decontamination lotion kits, the Trobigard combination drug-device auto-injector, NARCAN nasal spray for emergency opioid overdose reversal, Vivotif, an oral typhoid fever vaccine, and Vaxchora, a single-dose oral cholera vaccine. Emergent is also actively engaged in developing a robust pipeline of future solutions. This includes AP003 (a multidose naloxone nasal spray), AP007 (a sustained-release nalmefene injection for opioid use disorder), AV7909 (an anthrax vaccine), CGRD-001 (a pralidoxime chloride/atropine auto-injector), CHIKV VLP (a chikungunya virus vaccine), COVID-HIG (for SARS-CoV2 treatment), EGRD-001 (a diazepam auto-injector), SIAN (a cyanide poisoning antidote), and UniFlu (a universal influenza vaccine). Furthermore, the company extends its expertise through comprehensive contract development and manufacturing services (CDMO). These services cover drug substance and product manufacturing, packaging, along with technology transfer and advanced process and analytical development. Emergent BioSolutions Inc., founded in 1998, is headquartered in Gaithersburg, Maryland.
Mon, 02 Nov 2026
Emergent Biosolutions Q3 Earnings Call Highlights - Yahoo Finance
Mon, 02 Nov 2026
EBS: Higher margin guidance and debt reduction temper delivery-timing and naloxone pressures - TradingView
Mon, 02 Nov 2026
Emergent BioSolutions Q3 2026 Earnings Call Transcript - Benzinga
Mon, 02 Nov 2026
Emergent BioSolutions Inc Reports Q3 2026 Revenue of $110M and G - GuruFocus
Mon, 02 Nov 2026
Emergent BioSolutions swung from $51.2 million in profit to a $32.7 million loss. - Stock Titan
Fri, 30 Oct 2026
Emergent BioSolutions Inc. (EBS) Seasonal returns chart - Yahoo Finance UK
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 51 (M) |
| Shares Float | 49 (M) |
| Held by Insiders | 4.2 (%) |
| Held by Institutions | 90.4 (%) |
| Shares Short | 9,290 (K) |
| Shares Short P.Month | 10,840 (K) |
| EPS | -3.41 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.65 |
| Profit Margin | -23 % |
| Operating Margin | 28.3 % |
| Return on Assets (ttm) | 6.9 % |
| Return on Equity (ttm) | -40.3 % |
| Qtrly Rev. Growth | 66.3 % |
| Gross Profit (p.s.) | 7.57 |
| Sales Per Share | 15.02 |
| EBITDA (p.s.) | 4.58 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 98 (M) |
| Levered Free Cash Flow | 40 (M) |
| PE Ratio | -1.89 |
| PEG Ratio | 0.3 |
| Price to Book value | 0.96 |
| Price to Sales | 0.42 |
| Price to Cash Flow | 3.37 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|